- Home
- PHAR vs IIM Comparison
PHAR vs IIM Comparison
Compare PHAR & IIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- IIM
- Stock Information
- Founded
- PHAR 1988
- IIM 1993
- Country
- PHAR Netherlands
- IIM United States
- Employees
- PHAR N/A
- IIM N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- IIM Investment Managers
- Sector
- PHAR Health Care
- IIM Finance
- Exchange
- PHAR Nasdaq
- IIM Nasdaq
- Market Cap
- PHAR 731.1M
- IIM 550.7M
- IPO Year
- PHAR N/A
- IIM N/A
- Fundamental
- Price
- PHAR $10.00
- IIM $11.60
- Analyst Decision
- PHAR Strong Buy
- IIM
- Analyst Count
- PHAR 3
- IIM 0
- Target Price
- PHAR $30.00
- IIM N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- IIM 122.2K
- Earning Date
- PHAR 07-31-2025
- IIM 01-01-0001
- Dividend Yield
- PHAR N/A
- IIM 4.63%
- EPS Growth
- PHAR N/A
- IIM N/A
- EPS
- PHAR N/A
- IIM 0.02
- Revenue
- PHAR $320,708,000.00
- IIM N/A
- Revenue This Year
- PHAR $13.31
- IIM N/A
- Revenue Next Year
- PHAR $7.68
- IIM N/A
- P/E Ratio
- PHAR N/A
- IIM $591.50
- Revenue Growth
- PHAR 24.13
- IIM N/A
- 52 Week Low
- PHAR $6.65
- IIM $9.94
- 52 Week High
- PHAR $12.61
- IIM $12.32
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- IIM 43.64
- Support Level
- PHAR $9.99
- IIM $11.62
- Resistance Level
- PHAR $10.59
- IIM $11.68
- Average True Range (ATR)
- PHAR 0.35
- IIM 0.06
- MACD
- PHAR -0.14
- IIM 0.01
- Stochastic Oscillator
- PHAR 7.45
- IIM 23.68
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income that is exempt from federal income tax.